Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Total Current Liabilities (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Total Current Liabilities data on record, last reported at $52.4 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 19.15% year-over-year to $52.4 million; the TTM value through Sep 2025 reached $52.4 million, up 19.15%, while the annual FY2024 figure was $57.3 million, 146.33% up from the prior year.
  • Total Current Liabilities reached $52.4 million in Q3 2025 per ZBIO's latest filing, down from $53.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $57.3 million in Q4 2024 and bottomed at $23.3 million in Q4 2023.
  • Average Total Current Liabilities over 3 years is $46.6 million, with a median of $50.8 million recorded in 2025.
  • Peak YoY movement for Total Current Liabilities: surged 146.33% in 2024, then increased 19.15% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $23.3 million in 2023, then soared by 146.33% to $57.3 million in 2024, then dropped by 8.5% to $52.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $52.4 million in Q3 2025, $53.2 million in Q2 2025, and $49.1 million in Q1 2025.